

Giuseppe Bronte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3499606/publications.pdf>

Version: 2024-02-01

116
papers

2,986
citations

182225

30
h-index

223390

49
g-index

119
all docs

119
docs citations

119
times ranked

6055
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?. <i>Translational Oncology</i> , 2022, 15, 101300.	1.7	11
2	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. <i>Cancers</i> , 2022, 14, 1143.	1.7	23
3	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 866561.	2.2	15
4	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2352.	1.7	2
5	The application of cancer stem cell model in malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103698.	2.0	2
6	Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. , 2021, , .		0
7	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 669839.	1.3	4
8	Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 672219.	2.2	2
9	Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 809-817.	1.1	2
10	TMB in NSCLC: A Broken Dream?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6536.	1.8	31
11	Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 672233.	1.6	9
12	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. <i>Biomedicines</i> , 2021, 9, 1299.	1.4	10
13	The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772216.	1.8	3
14	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a <i>post hoc</i> analysis of the IBIS 3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591988899.	1.4	7
15	High-dose chemotherapy in a patient with coronavirus disease (COVID-19). <i>European Journal of Cancer</i> , 2020, 136, 130-131.	1.3	3
16	Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. <i>Lung Cancer</i> , 2020, 142, 47-50.	0.9	10
17	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. <i>Cancers</i> , 2020, 12, 915.	1.7	1
18	Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. <i>Journal of Clinical Medicine</i> , 2020, 9, 1047.	1.0	47

#	ARTICLE	IF	CITATIONS
19	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	19
20	Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?. <i>Journal of Oncology</i> , 2019, 2019, 1-6.	0.6	10
21	Targeting RET-rearranged non-small-cell lung cancer: future prospects. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 27-36.	1.3	40
22	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S265-S279.	1.3	17
23	New generation anaplastic lymphoma kinase inhibitors. <i>Translational Lung Cancer Research</i> , 2019, 8, S280-S289.	1.3	14
24	Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression. <i>Annals of Oncology</i> , 2019, 30, 339-340.	0.6	8
25	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	0.9	122
26	Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. <i>Frontiers in Oncology</i> , 2019, 9, 1519.	1.3	61
27	The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20688-e20688.	0.8	0
28	The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 545-545.	0.8	1
29	What to look for in cell-free DNA from breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 199-200.	1.1	2
30	Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small cell lung cancer. <i>Biological Reviews</i> , 2018, 93, 1735-1746.	4.7	23
31	Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 767-768.	1.1	1
32	Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?. <i>BMC Cancer</i> , 2018, 18, 348.	1.1	25
33	Petals and thorns in programmed death ligand 1 testing: Is all non-small cell lung cancer diagnostic material suitable?. <i>Cancer Cytopathology</i> , 2018, 126, 817-818.	1.4	0
34	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 3689-3697.	0.5	32
35	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35
36	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?. <i>Translational Oncology</i> , 2018, 11, 950-956.	1.7	24

#	ARTICLE	IF	CITATIONS
37	Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?. <i>Frontiers in Endocrinology</i> , 2018, 9, 137.	1.5	13
38	Sorafenib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 621-630.	0.9	29
39	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 83-105.	1.4	45
40	Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1042-1042.	0.8	1
41	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , 2016, 7, 47821-47830.	0.8	36
42	Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: is there room for diagnostic experience yet?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1490-E1492.	0.6	4
43	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016, 37, 7109-7118.	0.8	24
44	Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 615-623.	1.1	21
45	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 20-32.	2.0	31
46	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 188-197.	1.4	19
47	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	0.8	18
48	Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 150-157.	2.0	81
49	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 312-321.	2.0	30
50	Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1-5.	1.4	8
51	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	0.8	17
52	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	0.8	16
53	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	0.8	134
54	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , 2016, 7, 35803-35812.	0.8	9

#	ARTICLE	IF	CITATIONS
55	Multidisciplinary management of patients with liver metastasis from colorectal cancer. World Journal of Gastroenterology, 2016, 22, 7215.	1.4	67
56	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, 3565-3565.	0.8	0
57	Abstract 1855: Role of mTOR inhibition in triple-negative breast cancer. , 2016, , .		0
58	Study of mutational status of Sicilian GISTs patients. Annals of Oncology, 2015, 26, vi31.	0.6	0
59	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	3
60	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. Analytical Cellular Pathology, 2015, 2015, 1-19.	0.7	80
61	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget, 2015, 6, 35589-35601.	0.8	57
62	Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety, 2015, 14, 253-267.	1.0	43
63	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 95, 306-317.	2.0	27
64	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. Expert Opinion on Biological Therapy, 2015, 15, 1553-1566.	1.4	22
65	Cancer and the microbiome: potential applications as new tumor biomarker. Expert Review of Anticancer Therapy, 2015, 15, 317-330.	1.1	45
66	Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. Expert Opinion on Investigational Drugs, 2015, 24, 125-132.	1.9	5
67	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opinion on Biological Therapy, 2015, 15, 45-59.	1.4	8
68	Targeted Therapies in Melanoma. Current Clinical Pathology, 2015, , 211-227.	0.0	4
69	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS ONE, 2015, 10, e0133488.	1.1	110
70	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	0.8	77
71	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	0.8	30
72	Targeted Therapies in Hepatocellular Carcinoma. Current Clinical Pathology, 2015, , 137-145.	0.0	6

#	ARTICLE	IF	CITATIONS
73	VIPoma and PPoma. , 2015, , 223-231.		0
74	Targeted Therapies for Colorectal Cancer. Current Clinical Pathology, 2015, , 147-162.	0.0	0
75	Multi-institutional study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).. Journal of Clinical Oncology, 2015, 33, e12023-e12023.	0.8	0
76	Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.. Journal of Clinical Oncology, 2015, 33, 9540-9540.	0.8	0
77	The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.. Journal of Clinical Oncology, 2015, 33, e19030-e19030.	0.8	0
78	Germline copy number variation in the <i>YTHDC2</i> gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?. Expert Opinion on Therapeutic Targets, 2014, 18, 841-850.	1.5	44
79	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. Expert Opinion on Biological Therapy, 2014, 14, 103-114.	1.4	6
80	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Critical Reviews in Oncology/Hematology, 2014, 89, 300-313.	2.0	68
81	The role of targeted therapy for gastrointestinal tumors. Expert Review of Gastroenterology and Hepatology, 2014, 8, 875-885.	1.4	27
82	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. Expert Review of Anticancer Therapy, 2014, 14, 1173-1187.	1.1	25
83	How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 743-748.	1.4	15
84	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opinion on Biological Therapy, 2014, 14, 15-26.	1.4	17
85	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Reviews, 2014, 40, 990-1004.	3.4	70
86	Well-Being among Italian Medical Oncologists: An Exploratory Study. Oncology, 2014, 86, 72-78.	0.9	9
87	Ramucirumab and its use in gastric cancer treatment. Drugs of Today, 2014, 50, 613.	0.7	3
88	Targeted Therapies in Hepatocellular Carcinoma. Current Medicinal Chemistry, 2014, 21, 966-974.	1.2	19
89	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors: Did We Really Find the Target?. Current Drug Targets, 2014, 15, 1284-1292.	1.0	10
90	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Translational Lung Cancer Research, 2014, 3, 250-61.	1.3	44

#	ARTICLE	IF	CITATIONS
91	Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.. Journal of Clinical Oncology, 2014, 32, e20705-e20705.	0.8	0
92	Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).. Journal of Clinical Oncology, 2014, 32, e20513-e20513.	0.8	0
93	Dilemma in metastatic colorectal cancer: VEGF versus EGFR targeting. Expert Opinion on Therapeutic Targets, 2013, 17, 869-871.	1.5	8
94	Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 250-260.	1.0	1
95	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. Breast Cancer Research and Treatment, 2013, 140, 505-517.	1.1	29
96	The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg?. Critical Reviews in Oncology/Hematology, 2013, 86, 278-289.	2.0	8
97	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. Expert Opinion on Therapeutic Targets, 2013, 17, 1249-1261.	1.5	41
98	Monoclonal antibodies in gastrointestinal cancers. Expert Opinion on Biological Therapy, 2013, 13, 889-900.	1.4	18
99	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. BioMed Research International, 2013, 2013, 1-8.	0.9	32
100	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. Journal of Cellular Physiology, 2013, 229, n/a-n/a.	2.0	96
101	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1081-1088.	1.9	28
102	Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations. Oncology, 2013, 85, 306-311.	0.9	15
103	MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?. Oncogenesis, 2012, 1, e32-e32.	2.1	45
104	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. Oncology, 2012, 82, 75-82.	0.9	7
105	How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?. Current Women's Health Reviews, 2012, 8, 38-43.	0.1	0
106	The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opinion on Therapeutic Targets, 2012, 16, S103-S109.	1.5	117
107	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy, 2011, 11, 1433-1445.	1.4	15
108	EGFR genomic alterations in cancer prognostic and predictive values. Frontiers in Bioscience - Elite, 2011, E3, 879-887.	0.9	29

#	ARTICLE	IF	CITATIONS
109	Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules. <i>Current Drug Metabolism</i> , 2011, 12, 944-955.	0.7	15
110	HER2-positive male breast cancer: an update. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 45.	1.0	15
111	Anti-endothelin drugs in solid tumors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 27-40.	1.0	16
112	Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2010, 10, 55-67.	0.8	37
113	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, S21-S29.	3.4	128
114	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. <i>Cancer Treatment Reviews</i> , 2010, 36, S56-S61.	3.4	103
115	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. <i>Oncology</i> , 2009, 77, 57-68.	0.9	49
116	Sex Steroids, Carcinogenesis, and Cancer Progression. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 233-246.	1.8	34